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Background: Milrinone exhibits a sigmoidal relationship between plasma concentrations and the percent increase of cardiac index, with no 
additional hemodynamic benefit above 500 ng/ml. Milrinone may accumulate in renal dysfunction and increase arrhythmic risk in a concentration 
dependent manner. We hypothesized that heart failure (HF) patients with renal dysfunction would have elevated steady-state milrinone 
concentrations.
methods: 29 patients on continuous milrinone infusion at the time of plasma collection were enrolled in the Vanderbilt Heart Registry. Creatinine 
clearance (CrCl) was used to stratify patients into four groups: Group 1 (CrCl >60ml/min), Group 2 (CrCl 60-30 ml/min), Group 3 (CrCl <30 ml/
min), and Group 4 (hemodialysis). Plasma milrinone concentration was determined by liquid chromatography-mass spectrometry. Hemodynamic and 
arrhythmic effects were compared to a pre-milrinone baseline.
results: All patients (76% male; 39% ischemic cardiomyopathy) had stage D HF and an implanted cardiac defibrillator (ICD). There was no 
difference in the mean infusion rates (0.391 + 0.08 mcg/kg/min) (p=0.14) between groups. Of 8 post-milrinone ventricular tachycardia episodes 
requiring defibrillation, 6 occurred in Group 4 patients.
conclusions: Milrinone concentrations are markedly elevated in renal dysfunction. Quantification of milrinone concentrations may identify those at 
highest risk of ventricular arrhythmias. 
Group 1 (n=14)
Group 2
(n=10)
Group 3
(n=3)
Group 4
(n=2)
Milrinone (ng/ml) 451+ 243 591 + 293 1,575 + 962 6,252 + 4,409b
CI increasea 24% + 25% 44% + 45% 50% + 14% 15% + 35%
Data as mean + SD 
a Cardiac Index 
b p<0.05 vs all groups
